← Back to Search

Device

MST for Parkinson's Disease (MST-PD Trial)

N/A
Waitlist Available
Led By Fidel Vila-Rodriguez, MD, PhD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥50 years old
Confirmed diagnosis of Parkinson's disease based on UK Brain Bank criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights

MST-PD Trial Summary

This trial is testing whether a new therapy, Magnetic Seizure Therapy, is effective in treating depression in patients with Parkinson's Disease.

Eligible Conditions
  • Parkinson's Disease
  • Movement Disorders
  • Depression

MST-PD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are 50 years of age or older.
Select...
You have been diagnosed with Parkinson's disease using specific criteria from the UK Brain Bank.
Select...
You have Parkinson's disease at a moderate stage.
Select...
You have been diagnosed with a current major depressive episode using the MINI International Neuropsychiatric Interview, Version 6.
Select...
You have a score of 22 or higher on a test that measures how severe your depression is.
Select...
You are approved by a psychiatrist and an anaesthesiologist to receive convulsive therapy.
Select...
If you are taking antidepressant medication, you must be willing to continue taking the same medication during the study.
Select...
Meet the safety criteria for the study.

MST-PD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: recruitment
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: retention
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: side effects
Secondary outcome measures
Efficacy information to plan future definite trial

MST-PD Trial Design

1Treatment groups
Experimental Treatment
Group I: Magnetic Seizure TherapyExperimental Treatment1 Intervention
MST treatments will be administered using the MagPro XP MST with Cool TwinCoil.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,407 Previous Clinical Trials
1,766,529 Total Patients Enrolled
Fidel Vila-Rodriguez, MD, PhDPrincipal InvestigatorUniversity of British Columbia
2 Previous Clinical Trials
520 Total Patients Enrolled

Media Library

MagPro XP MST (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04784494 — N/A
Parkinson's Disease Research Study Groups: Magnetic Seizure Therapy
Parkinson's Disease Clinical Trial 2023: MagPro XP MST Highlights & Side Effects. Trial Name: NCT04784494 — N/A
MagPro XP MST (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04784494 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of patients participating in this research endeavor?

"Affirmative. Clinicaltrials.gov's records confirm that this trial, which was initially published on September 20th 2021 is actively recruiting participants. A total of 20 volunteers are required to participate in the study at a single medical site."

Answered by AI

Are participants invited to join the trial at this point in time?

"The clinical trial, which was initialised on the 20th of September 2021, is presently recruiting patients according to information stored on ClinicalTrials.gov. This data has been recently updated as of the 29th of September 2021."

Answered by AI
~6 spots leftby Mar 2025